Glutamate is the major excitatory neurotransmitter in the mammalian brain. Its rapid clearance after the release into the synaptic cleft is vital in order to avoid toxic effects and is ensured by several transmembrane transport proteins, so-called excitatory amino acid transporters (EAATs). Impairment of glutamate removal has been linked to several neurodegenerative diseases and EAATs have therefore received increased attention as therapeutic targets. O-benzylated L-threo-β-hydroxyaspartate derivatives have been developed previously as highly potent inhibitors of EAATs with TFB-TBOA ((2S,3S)-2-amino-3-((3-(4-(trifluoromethyl)benzamido)benzyl)oxy)succinic acid) standing out as low-nanomolar inhibitor. We report the stereoselective synthesis of all four stereoisomers of TFB-TBOA in less than a fifth of synthetic steps than the published route. For the first time, the inhibitory activity and isoform selectivity of these TFB-TBOA enantio-and diastereomers were assessed on human glutamate transporters EAAT1-3. Furthermore, we synthesized potent photoaffinity probes based on TFB-TBOA using our novel synthetic strategy.
Introduction
The involvement of glutamate in electrophysiological processes in the brain was first proposed and later confirmed in the 1950s. 1 It has been established since that the glutamatergic system regulates most of the excitatory activities in the central nervous system and it is estimated that 80-90% of the neurons use glutamate as neurotransmitter. A crucial step is the rapid termination of glutamate excitation since a high concentration of glutamate in the synaptic cleft, as upon release from pre-synaptic vesicles, is leading to excitotoxicity over time, which in turn can result in neuronal damage. 2 Rapid removal of extracellular glutamate is achieved by five selective transmembrane transport proteins belonging to the solute carrier (SLC) 1 family: EAAT1 (human gene SLC1A3, termed GLAST in rodents), EAAT2 (SLC1A2, GLT-1), EAAT3 (SLC1A1, EAAC1), EAAT4 (SLC1A6) and EAAT5 (SLC1A7). The first three are generally expressed in the brain and play a fundamental role in the termination of glutamate-mediated excitation at synapses. The latter two are very tissue specific and only found in Purkinje cells in the cerebellum (EAAT4) and in retina (EAAT5), respectively. EAAT3 is mainly located on the surface of post-synaptic neurons, whereas EAAT1 and EAAT2 are expressed in astrocytes. EAAT2
alone is responsible for the transport of >90% of extracellular glutamate into astrocytes. Not surprisingly, impairment of the glial glutamate transporters in particular, is leading to excitotoxic effects and death of neurons. In fact, several studies have linked the reduced function or expression of glutamate transporters to neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer, Parkinson and Huntington disease. 2, 3 Thus, enhancing glutamate transport is a viable therapeutic strategy for neuroprotection and corresponding studies both in vitro and in vivo in a mouse model of ALS, for instance,
have provided some encouraging results. 4 Addressing glutamate transporters with modulators does not only pose a challenge in terms of isoform selectivity and dynamic expression levels; it has very recently been shown for GLT-1 at least, that they are highly mobile at the surface of astrocytes, which in turn shapes synaptic transmission. 5, 6 Several research groups have investigated the activity of small molecules, in particular L-glutamate
(1) and L-aspartate (2) derivatives (Chart 1), to inhibit specific glutamate transporter isoforms. Early on, threo-L-β-hydroxyaspartate ((2S,3S)-3) was discovered to inhibit glutamate transport in synaptosomes and later identified as EAAC1 blocker. 8 Shimamoto and co-workers developed a series of The published asymmetric syntheses of L-TBOA ((2S,3S)-4) and TFB-TBOA ((2S,3S)-5) are rather elaborate (10 and 21 synthetic steps, respectively). 11, 19 Our goal was to establish a general and concise synthetic procedure to prepare derivatives of TFB-TBOA that we envision to develop into molecular probes for studying glutamate transporters in cells. Here, we report the synthesis of all four stereoisomers of TFB-TBOA (5) in only four synthetic steps and their inhibitory activity at human isoforms EAAT1-3.
Furthermore, we used our novel synthetic strategy to generate two potent photoaffinity probes based on the TFB-TBOA scaffold.
Results and Discussion

Chemistry
In our retrosynthetic analysis the benzyl ether in 5 was disconnected which led to bromide 6 and the key intermediate β-hydroxyaspartate 3 (Scheme 1). After some literature research we envisaged to use asymmetric aminohydroxlyation developed by Sharpless and co-workers [20] [21] [22] to install the two stereogenic centers in one reaction with high syn-selectivity to access the threo (2,3-syn) isomers (TBOA, Scheme 1, retrosynthetic path a). For the projected erythro (2,3-anti) isomers (EBOA, Scheme 1, retrosynthetic path b) we chose to utilize the Davis α-hydroxylation methodology-5-stereogenic centre at C-3. Thus, the projected synthetic plan would allow us to access all four stereoisomers of 5 in a very short four-step sequence starting either from fumarate 7 or protected aspartate 8.
Scheme 1. Retrosynthetic analysis and synthetic strategy to access all four isomers of 5.
First, dimethyl fumarate (7) was converted to the tert-butyl diester 9 in order to streamline deprotection conditions at the end of the synthesis (Scheme 2). Following a recently published modification 24 of the Sharpless aminohydroxylation protocol yielded protected hydroxyaspartate 10 with complete diastereoselectivity (only syn isomers formed) in 65%. The major improvement of this protocol is the use of 4-chlorobenzoyloxycarbamate (11) instead of the commonly used N-chlorocarbamate 25 that has to be formed in situ from tert-butyl carbamate and freshly prepared tert-butyl hypochlorite under aqueous basic conditions. In the presence of chiral ligand (DHQD)2PHAL the aminohydroxylation led to (2S,3S)-10 as major enantiomer, whereas using the pseudo-enantiomer (DHQ)2PHAL as ligand gave mainly (2R,3R)-10. In both cases the enantiomeric ratio (er) was determined to be 7:3 by chiral HPLC. It is important to run the aminohydroxylation reaction at -15°C in order to suppress formation of 1,2-diol side products resulting from asymmetric dihydroxylation that is also operational under the reaction conditions.
-6-
The free hydroxyl group of 10 was O-alkylated with bromide 6 26 (synthesis see Supporting Information).
Global deprotection using TFA in chloroform led to enantioenriched isomers (2S,3S)-5 or (2R,3R)-5. By following the same synthetic route as shown in Scheme 2 but omitting the chiral phthalazine ligand in the asymmetric aminohydroxylation step we also synthesized the racemic mixture of the 2,3-syn (threo) isomers of 5 for biological assessment. -7-
The synthesis of the two 2,3-anti (erythro) enantiomers started from enantiomerically pure N-Boc protected L-or D-aspartate that was first transformed into the corresponding di-tert-butyl ester 13 (Scheme 3) in order to simplify deprotection at the end. Unexpectedly, this protection step failed or resulted in very low yields when employing commonly used conditions. A recently published protocol 27 utilizing di-iso-propylcarbodiimide (DIPC), t-BuOH and CuCl as reagents ultimately worked best for us. The α-hydroxylation reaction developed by Davis and co-workers is a powerful methodology to stereoselectively install hydroxyl groups next to carbonyl functions. 28 In our particular case, treatment of fully protected aspartate 13 with NaHMDS at low temperature generated the -8- 
29,30
Chart 2. Structures of EAAT photoaffinity probes 15 and 16.
-9-
Biological Activity
With all four stereoisomers of 5 in hand, we next examined their ability to inhibit glutamate uptake into cells. To this end, HEK293 cell lines stably expressing either human EAAT1, 2 or 3 were generated and transport of [ 3 H]-L-glutamate into these cells in the presence of 5 was determined using a similar assay set up as described previously (using 10 M L-glutamate in the transport assay). 31 For all four stereoisomers of 5 we observed dose-dependent inhibition of [ Glutamate concentration used in the transport assay was 10 M. All data are means of 3 measurements ± SD.
-10-Overall, the 2,3-syn (threo, TFB-TBOA) isomers of 5 are more potent inhibitors of glutamate uptake facilitated by EAAT1, 2 or 3 than the 2,3-anti (erythro, TFB-EBOA) isomers by one to two orders of magnitude (Table) . This is in line with what was observed for the stereoisomers of β-benzyloxyaspartate, where for instance L-TBOA ((2S,3S)-4) was a more active inhibitor than L-EBOA ((2S,3R)-4). 11 It is interesting to note, however, that the difference in inhibitory potency of the β-benzyloxyaspartate stereoisomers 4 is more or less pronounced depending on the glutamate transporter isoform studied; an observation that we have also made with our synthesized stereoisomers of 5. M for EAAT1, EAAT2 and EAAT3, respectively).
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Conclusions
We have developed a short and concise synthesis for the preparation of all four stereoisomers of TFB-TBOA, a known and potent inhibitor of glutamate uptake by excitatory amino acid transporters EAAT1-3. Our only four-step synthetic route relies on the Sharpless asymmetric aminohydroxylation to access the 2,3-syn (threo) isomers, whilst we have employed the Davis asymmetric α-hydroxylation to prepare the 2,3-anti (erythro) isomers of TFB-TBOA. For the first time all four stereoisomers have been tested on human glutamate transporters EAAT1-3 and our data show that the correct relative stereochemistry is crucial for high inhibitory activity, with the 2,3-syn (threo) isomers being clearly more active than the 2,3-anti (erythro) isomers. On the other hand, the absolute stereochemistry plays a minor role and enantioselectivity was effectively only observed for EAAT3. This observation implies that it is probably not necessary to use enantiomerically pure (S,S)-TFB-TBOA for biological studies but the racemic mixture, that is very easily synthesized following our developed protocol, is equally potent. Following our synthetic strategy, two TFB-TBOA-derived photoaffinity probes have been synthesized which exhibited sub-micromolar to micromolar inhibitory activity at EAAT1-3 and therefore could be useful molecular tools for photo-crosslinking studies. Efforts to develop further EAAT molecular probes with improved activities are underway in our laboratory and will be reported in due course.
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